Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04836975
Status:
COMPLETED
Last Update Posted:
2024-01-18
First Post:
2021-04-06
Brief Title:
Reveal the Patterns of Presentation Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicenter Retrospective Observational Study to Reveal the Patterns of Presentation Management and Outcome of Patients With Small Cell Lung Cancer SCLC and Stage III Non-Small Cell Lung Cancer NSCLC in Saudi Arabia
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REVEAL
Brief Summary:
A retrospective multi-centre observational study to describe the treatment patterns the demographic clinical outcomes treatment effectiveness and healthcare resource utilization HCRU for patients diagnosed with primary Small Cell Lung Cancer SCLC Extensive stage Limited Stageand stage III NSCLC in a real-world setting
Detailed Description:
A retrospective multi-centre observational study to describe the treatment patterns the demographic clinical outcomes treatment effectiveness and healthcare resource utilization HCRU for patients diagnosed with primary Small Cell Lung Cancer SCLC Extensive stage Limited Stageand stage III NSCLC in a real-world setting
Cohort of patients diagnosed with primary SCLC limited or extensive stage or stage III NSCLC aims to characterize the treatment patterns from the index date defined as the date of initial diagnosis of locally advanced stage III NSCLC and SCLC to the end of follow-up defined as the earliest of death last available medical record or end of the observation period defined as the date of data abstraction including the type of treatment received duration of each treatment regimen and reasons for stopping treatment regimen
The study population will be identified by participating physicians involved in the diagnosis treatment and management of these patients through the review of established patient medical records Eligible patients both alive and deceased will have their data anonymously abstracted from their medical records into a centrally designed electronic case report form eCRF
Cohort of patients diagnosed with primary SCLC limited or extensive stage or stage III NSCLC aims to characterize the treatment patterns from the index date defined as the date of initial diagnosis of locally advanced stage III NSCLC and SCLC to the end of follow-up defined as the earliest of death last available medical record or end of the observation period defined as the date of data abstraction including the type of treatment received duration of each treatment regimen and reasons for stopping treatment regimen
The study population will be identified by participating physicians involved in the diagnosis treatment and management of these patients through the review of established patient medical records Eligible patients both alive and deceased will have their data anonymously abstracted from their medical records into a centrally designed electronic case report form eCRF
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None